Fig. 5: Treatment with the SAR–taFv combination can efficiently eradicate leukemia and enhance survival in vivo.

A Schematic overview of the experimental setup for (B and C). NSG mice were inoculated i. v. with 2 × 10⁶ MV4-11-LUC-GFP tumor cells. Mice were treated with a single i. v. injection of T cells. Antibody treatment was given by several i. p. injections of the anti-E3–anti-CD33 molecule (2.8 μg/injection) or a control anti-E3–anti-CD19 molecule (2.8 μg/injection), as indicated by the arrows in the figure. Treatment groups were as follows: SAR T cells and anti-E3–anti-CD33 (n = 7), SAR T cells and anti-E3–anti-CD19 (n = 6), SAR T cells only (n = 5), anti-E3–anti-CD33 only (n = 6), PBS (n = 6), and anti-CD33 CAR T cells (n = 5). B Percentage survival readout. † indicates sacrifice of mice suffering from CAR-related toxicity. C In vivo imaging data displaying luminescent signal in counts for all experimental groups from treatment day onwards (Days 0, 7, 14, 17, 21, 28, and 42). D Schematic overview of the experimental setup for (E and F). NSG mice were inoculated i. v. with 10⁶ THP-1-LUC-GFP tumor cells. Mice were treated with a single i. v. injection of T cells with or without the anti-E3–anti-CD33 molecule (2.8 μg /injection) or a control anti-E3–anti-CD19 molecule (2.8 μg /injection). Treatment groups were as follows: SAR T cells and anti-E3–anti-CD33 (n = 5), SAR T cells and anti-E3–anti-CD19 (n = 5), SAR T cells only (n = 5), anti-E3–anti-CD33 only (n = 5), and PBS (n = 5). F Percentage survival readout. G In vivo imaging data displaying luminescent signal in all experimental groups from treatment day onwards (Days 0, 24, 28, 38, 45, 52). For statistical analysis of survival data, the log-rank test was applied. All in vivo experiments were carried out twice. One representative experiment is shown per xenograft model.